NCT03948841

Brief Summary

The aim of our study is to assess variability of measurements of liver metastases from neuroendocrine tumors (NET) on different magnetic resonance imaging (MRI) sequences. In this institutional review board-approved retrospective study from January 2011 to December 2012, all liver MRIs performed at our department in patients with proven liver metastases from NETs and with at least one measurable lesion according to Response evaluation criteria in solid tumors (RECIST 1.1) were included.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
41

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jan 2011

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2011

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2012

Completed
3.8 years until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2016

Completed
2.7 years until next milestone

First Submitted

Initial submission to the registry

May 10, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

May 14, 2019

Completed
Last Updated

May 14, 2019

Status Verified

May 1, 2019

Enrollment Period

1.9 years

First QC Date

May 10, 2019

Last Update Submit

May 10, 2019

Conditions

Neuroendocrine Tumors

Keywords

Neuroendocrine tumor

Outcome Measures

Primary Outcomes (1)

  • variability of measurements of liver metastases from neuroendocrine tumors (NET) on different magnetic resonance imaging (MRI) sequences.

    calculation of intraclass correlation coefficient

    Day 0

Study Arms (1)

Neuroendocrine tumor

Patients with liver metastasis from neuroendocrine tumor

Other: magnetic resonance imaging

Interventions

magnetic resonance imagingOTHER
Neuroendocrine tumor

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with liver metastasis from neuroendocrine tumor with a magnetic resonance imaging in Reims university hospital.

You may qualify if:

  • Patients with liver metastasis from neuroendocrine tumor
  • Patients with a magnetic resonance imaging in Reims university hospital
  • Patients with at least one measurable lesion according to Response evaluation criteria in solid tumors

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Damien JOLLY

Reims, France

Location

Related Publications (1)

  • Lestra T, Kanagaratnam L, Mule S, Janvier A, Brixi H, Cadiot G, Dohan A, Hoeffel C. Measurement variability of liver metastases from neuroendocrine tumors on different magnetic resonance imaging sequences. Diagn Interv Imaging. 2018 Feb;99(2):73-81. doi: 10.1016/j.diii.2017.12.009. Epub 2018 Jan 12.

    PMID: 29339222BACKGROUND

MeSH Terms

Conditions

Neuroendocrine Tumors

Interventions

Magnetic Resonance Spectroscopy

Condition Hierarchy (Ancestors)

Neuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeNeoplasmsNeoplasms, Nerve Tissue

Intervention Hierarchy (Ancestors)

Spectrum AnalysisChemistry Techniques, AnalyticalInvestigative Techniques

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 10, 2019

First Posted

May 14, 2019

Study Start

January 1, 2011

Primary Completion

December 1, 2012

Study Completion

September 1, 2016

Last Updated

May 14, 2019

Record last verified: 2019-05

Locations

FR(1)